期刊文献+

吡格列酮对糖尿病大鼠胰岛β细胞的保护作用及机制探讨 被引量:2

在线阅读 下载PDF
导出
摘要 目的观察吡格列酮对糖尿病大鼠胰岛β细胞的保护作用,并探讨其机制。方法将雄性Wistar大鼠30只随机分为三组各10只。模型组、吡格列酮组采用腹腔注射链脲佐菌素建立糖尿病大鼠模型,对照组腹腔注射等量枸橼酸缓冲液;造模成功后吡格列酮组予吡格列酮10 mg/(kg·d)灌胃,另两组予等量生理盐水灌胃。16周后断尾取血测空腹血糖(FPG),心包取血测糖化血红蛋白(HbA1c)和空腹胰岛素水平(FINS),并计算胰岛素抵抗指数(HOMA-IR),另取胰腺组织行HE染色,电镜下观察病理变化。结果吡格列酮组FPG、HbA1c、FINS、HOMA-IR水平明显低于模型组,病理改变轻于模型组。结论吡格列酮对糖尿病大鼠胰岛β细胞有保护作用,其机制可能为降低血糖、HbA1c和FINS,改善糖毒性和胰岛素抵抗。
出处 《山东医药》 CAS 北大核心 2011年第15期44-45,共2页 Shandong Medical Journal
  • 相关文献

参考文献5

  • 1Miyazaki Y, Matsuda M, Defronzo RA. Dose-response effect of piglitazone on insulin sensitivity and insulin secretion in type 2 diabetes [J]. Diabetes Care,2002,25(3) :517-523.
  • 2刘卓.吡格列酮对2型糖尿病患者糖和脂质代谢的影响[J].现代医院,2005,5(6):13-15. 被引量:4
  • 3陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 4王长江,刘树琴,章秋,杨明功,叶山东,王德全,罗佐杰,阎胜利.盐酸吡格列酮治疗2型糖尿病的疗效及安全性[J].中国临床药理学杂志,2002,18(3):167-170. 被引量:14
  • 5Rodrfguez A, Revirlego J, Polavieja P, et al. Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or mefformin for the treatment of type 2 diabetes mellitus [ J ]. Med Clin,2008,131 (19) :721-730.

二级参考文献22

  • 1[1]Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin endocrinol Diabetes, 1998; 106:369~372.
  • 2[2]Haffner SM. Epdemiology of insulin resistance and its relation to coronary artery disease. American J Cardiology, 1999; 84:11 ~ 14.
  • 3[3]Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferactor-activated receptor γ. J Biol Chem, 1995; 270:129~153.
  • 4[4]Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes,1997; 46:1393~ 1399.
  • 5[5]Kemnitz JW, Elson DF, Roecker EB, et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels,and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes, 1994; 43:204~211.
  • 6[6]Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther, 2001; 23:1792~1823.
  • 7[7]Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 2001; 12:413~423.
  • 8[8]Hanefeld M, Belcher G. Safety profile of pioglitazone. Iht J Clin Pract, 2001, 121:27~31.
  • 9[9]Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24 873~888.
  • 10[10]Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.Clin Ther, 2000; 22:1395~1409.

共引文献1113

同被引文献45

引证文献2

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部